Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

87 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Depleting hepatitis B virus relaxed circular DNA is necessary for resolution of infection by CRISPR-Cas9.
Kostyushev D, Kostyusheva A, Brezgin S, Ponomareva N, Zakirova NF, Egorshina A, Yanvarev DV, Bayurova E, Sudina A, Goptar I, Nikiforova A, Dunaeva E, Lisitsa T, Abramov I, Frolova A, Lukashev A, Gordeychuk I, Zamyatnin AA Jr, Ivanov A, Chulanov V. Kostyushev D, et al. Among authors: chulanov v. Mol Ther Nucleic Acids. 2023 Feb 4;31:482-493. doi: 10.1016/j.omtn.2023.02.001. eCollection 2023 Mar 14. Mol Ther Nucleic Acids. 2023. PMID: 36865089 Free PMC article.
Technological aspects of manufacturing and analytical control of biological nanoparticles.
Brezgin S, Parodi A, Kostyusheva A, Ponomareva N, Lukashev A, Sokolova D, Pokrovsky VS, Slatinskaya O, Maksimov G, Zamyatnin AA Jr, Chulanov V, Kostyushev D. Brezgin S, et al. Among authors: chulanov v. Biotechnol Adv. 2023 May-Jun;64:108122. doi: 10.1016/j.biotechadv.2023.108122. Epub 2023 Feb 20. Biotechnol Adv. 2023. PMID: 36813011 Review.
Transient and tunable CRISPRa regulation of APOBEC/AID genes for targeting hepatitis B virus.
Kostyushev D, Brezgin S, Kostyusheva A, Ponomareva N, Bayurova E, Zakirova N, Kondrashova A, Goptar I, Nikiforova A, Sudina A, Babin Y, Gordeychuk I, Lukashev A, Zamyatnin AA Jr, Ivanov A, Chulanov V. Kostyushev D, et al. Among authors: chulanov v. Mol Ther Nucleic Acids. 2023 Apr 20;32:478-493. doi: 10.1016/j.omtn.2023.04.016. eCollection 2023 Jun 13. Mol Ther Nucleic Acids. 2023. PMID: 37187708 Free PMC article.
Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase 3 randomized trial.
Wedemeyer H, Aleman S, Brunetto M, Blank A, Andreone P, Bogomolov P, Chulanov V, Mamonova N, Geyvandova N, Morozov V, Sagalova O, Stepanova T, Berger A, Ciesek S, Manuilov D, Mercier RC, Da BL, Chee GM, Li M, Flaherty JF, Lau AH, Osinusi A, Schulze Zur Wiesch J, Cornberg M, Zeuzem S, Lampertico P. Wedemeyer H, et al. Among authors: chulanov v. J Hepatol. 2024 May 9:S0168-8278(24)00333-7. doi: 10.1016/j.jhep.2024.05.001. Online ahead of print. J Hepatol. 2024. PMID: 38734383
m6A Methylation in Regulation of Antiviral Innate Immunity.
Karandashov I, Kachanov A, Dukich M, Ponomareva N, Brezgin S, Lukashev A, Pokrovsky VS, Chulanov V, Kostyusheva A, Kostyushev D. Karandashov I, et al. Among authors: chulanov v. Viruses. 2024 Apr 13;16(4):601. doi: 10.3390/v16040601. Viruses. 2024. PMID: 38675942 Free PMC article. Review.
Progress towards elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission update.
Cooke GS, Flower B, Cunningham E, Marshall AD, Lazarus JV, Palayew A, Jia J, Aggarwal R, Al-Mahtab M, Tanaka Y, Jeong SH, Poovorawan K, Waked I, Hiebert L, Khue PM, Grebely J, Alcantara-Payawal D, Sanchez-Avila JF, Mbendi C, Muljono DH, Lesi O, Desalegn H, Hamid S, de Araujo A, Cheinquer H, Onyekwere CA, Malyuta R, Ivanchuk I, Thomas DL, Pimenov N, Chulanov V, Dirac MA, Han H, Ward JW. Cooke GS, et al. Among authors: chulanov v. Lancet Gastroenterol Hepatol. 2024 Apr;9(4):346-365. doi: 10.1016/S2468-1253(23)00321-7. Epub 2024 Feb 15. Lancet Gastroenterol Hepatol. 2024. PMID: 38367629 Review.
[Use of a combination of the virus-neutralizing monoclonal antibodies casirivimab and imdevimab for mild to moderate COVID-19 in patients at high risk of progression: Results of the non-interventional observational study].
Lebedkina MS, Fomina DS, Mutovina ZY, Mаrkina UA, Bogomolov PO, Chulanov VP, Lysenko MA, Alexeeva EI. Lebedkina MS, et al. Among authors: chulanov vp. Ter Arkh. 2023 Aug 17;95(6):494-499. doi: 10.26442/00403660.2023.06.202297. Ter Arkh. 2023. PMID: 38158969 Russian.
87 results